



Press Release October 11, 2016

Genovis signs license agreement with Life Technologies Corporation

Genovis has entered into a license agreement with Life Technologies a wholly owned subsidiary of Thermo Fisher Scientific and is launching a unique new technology for labeling antibodies. The first product, GlyCLICK™, will be launched in the autumn.

Labeling of antibodies includes several elements in the chain from development, preclinical, diagnostic and therapeutic applications in the pharmaceutical industry. By combining Genovis' unique enzymes with SiteClick™ technology from Life Technologies antibodies will be labeled precisely and completely at the same site each time, regardless of the type of antibody or its origin. Genovis will focus sales and marketing resources for GlyCLICK on the preclinical market in the biopharma industry where the company already has the majority of its customer base. Initially, the technology will be marketed in the market for preclinical imaging. The reagent market for this segment is estimated to be approximately USD 500 million for 2017 (Markets and Markets).

“I am very pleased about the collaboration with Life Technologies, which now gives us a unique and extremely interesting product. We will establish the product within preclinical research, though we see several potential clinical applications moving forward. The field of diagnostic applications is interesting, but the next generation of antibody drugs, known as Antibody Drug Conjugates (ADC), could also benefit from the new technology platform, which offers a precise and exact end product that the industry has been requesting,” says Fredrik Olsson, CEO of Genovis.

For more information, please contact:
Fredrik Olsson, CEO, Genovis AB
T: +46 (0)46-10 12 33
E: fredrik.olsson@genovis.com

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.



MORE ABOUT LABELING ANTIBODIES

Labeling antibodies with various markers is a technique used in several areas of pharmaceutical research and development. With the technology currently available in the market, the marker can attach randomly in different places on the antibody, and in many cases it could have a negative effect on the function of the antibody. In addition, the position of the marker may vary depending on the antibody that is labeled. Using the new GlyCLICK™ technology platform, the label always attaches at precisely the same site and it is possible to label with many different markers, which makes the technology both versatile and scalable.

For more information about GlyCLICK™: <http://www.genovis.com/products/glyclick/>

ABOUT GENOVIS

Genovis' business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Consensus is the Company's Certified Advisor, t: +46(0) 31 745 50 00

SiteClick™

SiteClick™ is provided under an intellectual property license from Life Technologies Corporation. The trademark SiteClick™ is the property of Life Technologies Corporation.

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the contact person set out above, on October 11, 2016.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.